Resolution Therapeutics to Present at EASL Congress 2024

Resolution Therapeutics Limited, a prominent clinical-stage biopharmaceutical company, is set to present two pivotal abstracts at the upcoming European Association for the Study of the Liver (EASL) Congress 2024. The conference will be held in Milan, Italy, from June 5-8, 2024. The presentations will highlight extended follow-up data from the MATCH Phase 2 trial and introduce new insights into the company's innovative discovery platform for engineering and cryopreserving macrophages for therapeutic use in patients with end-stage liver disease (ESLD).

The first abstract, a late-breaking presentation, will provide extended follow-up data from the MATCH Phase 2 trial. This study focuses on the beneficial effects of autologous macrophage therapy on clinical outcomes in patients with compensated cirrhosis. This presentation will take place on Wednesday, June 5, 2024, at 8:30 a.m. CEST, identified by Poster ID: LBP-007 and will be presented by Dr. Paul Brennan from the University of Dundee.

The second abstract discusses Resolution's discovery platform, which is instrumental in differentiating, engineering, and cryopreserving macrophages for therapeutic applications. This new data will be showcased in a session dedicated to experimental and pathophysiology aspects of cirrhosis and its complications, also scheduled for June 5, 2024, at 8:30 a.m. CEST. The poster, identified by Poster ID: WED-090, will be presented by Lara Campana, Ph.D., Vice President of Research Operations at Resolution Therapeutics.

Dr. Amir Hefni, Chief Executive Officer of Resolution Therapeutics, emphasized that these poster presentations build on the MATCH Phase 2 data previously presented at the AASLD Annual Meeting. He expressed that the new data further validates the transformative potential of macrophage cell therapy and underscores the robustness of Resolution’s discovery platform. Dr. Hefni highlighted the company's commitment to advancing its first-in-human Phase 1/2 EMERALD study for ESLD, set to begin in the third quarter of this year.

In addition to the poster presentations, Stuart Forbes, Ph.D., Professor of Transplantation and Regenerative Medicine at the University of Edinburgh and Co-founder of Resolution, will deliver a presentation titled "Macrophage therapy for liver disease" on Tuesday, June 4, 2024. This presentation will be part of the 3rd International Symposium on Regenerative Hepatology, organized by the EASL Regenerative Hepatology Consortium in Milan.

Resolution Therapeutics is at the forefront of developing macrophage cell therapies designed to treat inflammatory organ diseases. The company leverages its proprietary platform to engineer autologous macrophages with distinct pro-regenerative properties, aiming to deliver superior patient outcomes. Their lead candidate, RTX001, targets end-stage liver disease and is supported by preclinical data demonstrating significant anti-fibrotic and anti-inflammatory effects compared to non-engineered macrophages. The company’s research initiatives are not limited to liver diseases but also extend to other indications where engineered macrophages can offer therapeutic benefits.

The EASL Congress is a significant event for professionals in hepatology, offering a platform for presenting and discussing the latest research and advancements in liver diseases. EASL, founded in 1966, is dedicated to liver research excellence, clinical practice, and education in hepatology, serving over 5,300 members from 112 countries.

In summary, Resolution Therapeutics' participation in the EASL Congress 2024 underscores its commitment to advancing macrophage cell therapy for liver disease and other inflammatory organ diseases, reflecting its promise to deliver transformative therapeutic outcomes.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!